Managed Account Advisors’s Standard BioTools LAB Stock Holding History

Managed Account Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$1.48M	Buy	61,015 +342	+0.6%	+$10.8K	﹤0.01%	1952
2015 Q1	$2.55M	Buy	60,673 +2,863	+5%	+$113K	﹤0.01%	1730
2014 Q4	$1.95M	Buy	57,810 +13,660	+31%	+$387K	﹤0.01%	1827
2014 Q3	$1.08M	Buy	44,150 +1,238	+3%	+$34.8K	﹤0.01%	2021
2014 Q2	$1.26M	Buy	+42,912	New	+$1.38M	﹤0.01%	1949
2014 Q1	–	Sell	-5,822	Closed	-$223K	–	2644
2013 Q4	$223K	Buy	+5,822	New	+$171K	﹤0.01%	2191

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Managed Account Advisors's LAB Position: Q2 2015 in Review

Managed Account Advisors increased its Standard BioTools (LAB) stake by 0.56% in Q2 2015, buying an estimated $10.8K and bringing the position to 61,015 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Managed Account Advisors first reported a position in LAB in Q4 2013 and has held it in 6 quarters since. The position peaked at $2.55M in Q1 2015. 107 funds tracked by Wall St. Rank hold LAB as of Q2 2015.

Managed Account Advisors held 61,015 shares of Standard BioTools worth $1.48M as of Q2 2015.
Managed Account Advisors bought 342 Standard BioTools shares in Q2 2015, an estimated $10.8K.
Standard BioTools made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1952 holding.
Managed Account Advisors first reported a position in Standard BioTools in Q4 2013 and has held it in 6 quarters since.
Managed Account Advisors's Standard BioTools position peaked at $2.55M in Q1 2015.
107 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.